IRIS
SANTINI, DAMIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 262
EU - Europa 145
AS - Asia 100
OC - Oceania 2
SA - Sud America 2
AF - Africa 1
Totale 512
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 256
IE - Irlanda 103
CN - Cina 82
FI - Finlandia 21
SG - Singapore 12
DE - Germania 8
CA - Canada 6
BE - Belgio 3
IT - Italia 3
JP - Giappone 3
AU - Australia 2
GB - Regno Unito 2
AL - Albania 1
AR - Argentina 1
IL - Israele 1
IN - India 1
LV - Lettonia 1
MU - Mauritius 1
MY - Malesia 1
NL - Olanda 1
PE - Perù 1
SE - Svezia 1
UA - Ucraina 1
Totale 512
Salva come PNG Salva come JPEG
Città #
Dublin 103
Chandler 74
Beijing 43
Ashburn 23
Helsinki 21
Shanghai 18
Boardman 15
Lawrence 15
Medford 15
Princeton 15
Singapore 10
Wilmington 9
Chicago 8
Nanjing 7
Toronto 6
Ann Arbor 5
Nanchang 4
Brussels 3
Fairfield 3
Jiaxing 3
Tokyo 3
Canberra 2
Changsha 2
London 2
New York 2
Norwalk 2
Shenyang 2
Cambridge 1
Dearborn 1
Fremont 1
Hebei 1
Jerusalem 1
Lima 1
Pavia 1
Piscataway 1
Pognana Lario 1
Pune 1
Riga 1
Tianjin 1
Tirana 1
Torino 1
Washington 1
Woodbridge 1
Totale 431
Salva come PNG Salva come JPEG
Nome #
Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis? 44
Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas 43
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 40
Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors 39
Natural history of malignant bone disease in gastric cancer; final results of a multicenter bone metastatis survey 38
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis 35
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis 35
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker? 34
PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises 33
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma 33
The effect of a treatment delay on outcome in metastatic renal cell carcinoma 33
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 32
Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma 31
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 30
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 30
Totale 530
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3.196
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.196
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202059 0 0 0 0 0 0 13 3 0 24 19 0
2020/202110 0 0 0 0 0 2 0 7 0 0 1 0
2021/202267 0 1 7 0 1 0 0 5 1 1 14 37
2022/2023237 31 27 3 8 15 18 0 11 115 2 3 4
2023/202489 19 16 3 2 4 20 13 1 2 1 3 5
2024/202546 20 15 11 0 0 0 0 0 0 0 0 0
Totale 530